5,6,7,8-Tetrahydro-1,7-naphthyridine dihydrochloride | 351038-62-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5,6,7,8-Tetrahydro-1,7-naphthyridine dihydrochloride
• 英文别名: 5,6,7,8-tetrahydro-1,7-naphthyridine;dihydrochloride
• CAS: 351038-62-5
• 化学式: C8H12Cl2N2
• 分子量: 207.1
• InChiKey: ZRMBMVOGUOPEAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  24.9
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• [EN] MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS MACROCYCLIQUES DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222353A1

  公开（公告）日：2021-11-04

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽精氨酸脱亚氨酶（PADs）相关的疾病的新化合物，例如肽精氨酸脱亚氨酶类型4（PAD4）。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的药物组合物。
• [EN] PROBES FOR IMAGING HUNTINGTIN PROTEIN<br/>[FR] SONDES D'IMAGERIE DE LA PROTÉINE HUNTINGTINE
  申请人：CHDI FOUNDATION INC

  公开号：WO2016033445A1

  公开（公告）日：2016-03-03

  Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

  提供了包含化合物I式或其药用可接受盐的成像试剂，以及它们的使用方法。
• NOVEL FURANONE DERIVATIVE
  申请人：Irie Takayuki

  公开号：US20140018533A1

  公开（公告）日：2014-01-16

  To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I): wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents —COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

  提供一种新的呋喃酮衍生物，以及包含该衍生物的药物。该呋喃酮衍生物由以下式（I）表示：其中A代表—COOR1或氢原子；R1代表氢原子、可选择取代的碳氢基团或可选择取代的杂环基团；R2和R3相同或不同，每个独立地代表氢原子、可选择取代的碳氢基团、可选择取代的苯基团、可选择取代的杂环基团、可选择取代的杂环融合环或可选择取代的氨基团；或者，R2和R3与它们连接的氮原子一起，可以形成可选择取代的杂环或可选择取代的杂环融合环；R4代表氢原子或卤素原子；但当A代表—COOR1时，R2和R3不能同时是可选择取代的氨基团，当A代表氢原子时，R3代表氢原子。
• [EN] INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2022140390A1

  公开（公告）日：2022-06-30

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽基精氨酸脱亚胺酶（PADs）相关的疾病（例如肽基精氨酸脱亚胺酶4型（PAD4））的新化合物。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的制药组合物。